NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,664,731 | -9.6% | 2,795,049 | -12.7% | 0.00% | -20.0% |
| Q2 2023 | $1,841,695 | +29.3% | 3,201,835 | +58.0% | 0.01% | +25.0% |
| Q1 2023 | $1,424,392 | +58.5% | 2,026,450 | +409.5% | 0.00% | +33.3% |
| Q4 2022 | $898,901 | -66.6% | 397,744 | -52.7% | 0.00% | -66.7% |
| Q3 2022 | $2,694,000 | +67.4% | 841,775 | +98.8% | 0.01% | +80.0% |
| Q2 2022 | $1,609,000 | -36.8% | 423,420 | -10.4% | 0.01% | -37.5% |
| Q1 2022 | $2,546,000 | -76.2% | 472,391 | -40.4% | 0.01% | -65.2% |
| Q4 2021 | $10,708,000 | +44.4% | 792,611 | +92.0% | 0.02% | +35.3% |
| Q3 2021 | $7,413,000 | +9.9% | 412,754 | +5.0% | 0.02% | +13.3% |
| Q2 2021 | $6,745,000 | +270.2% | 393,061 | +331.5% | 0.02% | +200.0% |
| Q1 2021 | $1,822,000 | +203.7% | 91,092 | +158.2% | 0.01% | +150.0% |
| Q4 2020 | $600,000 | -83.9% | 35,282 | -84.3% | 0.00% | -84.6% |
| Q3 2020 | $3,720,000 | -42.8% | 224,227 | -20.1% | 0.01% | -59.4% |
| Q2 2020 | $6,503,000 | +223.9% | 280,782 | +201.9% | 0.03% | +433.3% |
| Q4 2019 | $2,008,000 | -19.3% | 93,013 | +33.0% | 0.01% | -25.0% |
| Q2 2019 | $2,488,000 | -8.9% | 69,932 | -15.9% | 0.01% | -27.3% |
| Q4 2018 | $2,732,000 | -65.0% | 83,113 | -35.2% | 0.01% | -47.6% |
| Q3 2018 | $7,816,000 | -70.2% | 128,215 | -76.1% | 0.02% | -73.1% |
| Q2 2018 | $26,192,000 | +4560.5% | 536,393 | +2192.3% | 0.08% | +3800.0% |
| Q3 2017 | $562,000 | -35.1% | 23,400 | -47.2% | 0.00% | -33.3% |
| Q2 2017 | $866,000 | -87.5% | 44,320 | -85.0% | 0.00% | -87.0% |
| Q1 2017 | $6,932,000 | -44.3% | 295,376 | -70.9% | 0.02% | -52.1% |
| Q4 2016 | $12,442,000 | +5.1% | 1,013,992 | +47.2% | 0.05% | +11.6% |
| Q3 2016 | $11,833,000 | +1197.5% | 688,763 | +1071.2% | 0.04% | +760.0% |
| Q4 2014 | $912,000 | +473.6% | 58,807 | +286.6% | 0.01% | +400.0% |
| Q3 2013 | $159,000 | – | 15,212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |